An Open-Label, Single-Arm, Multicenter, Phase 2 Trial to Evaluate Cabozantinib (CABO) plus Durvalumab (DURVA) in Patients with Advanced and Chemotherapy-Treated Bladder Carcinoma of Urothelial and Non-Urothelial Histology

Trial Profile

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial to Evaluate Cabozantinib (CABO) plus Durvalumab (DURVA) in Patients with Advanced and Chemotherapy-Treated Bladder Carcinoma of Urothelial and Non-Urothelial Histology

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Durvalumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2018 New trial record
    • 16 Feb 2018 According to trial design presented at the 2018 Genitourinary Cancers Symposium, an interim analysis is planned after 24 months (50% expected events) based on predictive power (PP) calculation.
    • 16 Feb 2018 According to trial design presented at the 2018 Genitourinary Cancers Symposium, patients will be accrued over 36 months and follow-up may be closed 12 months after the end of accrual.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top